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Abstract
Background: Clinical guidelines and public health authorities lack recommendations on scalable approaches to
defining and monitoring the occurrence and severity of bleeding in populations prescribed antithrombotic therapy.
Methods: We examined linked primary care, hospital admission and death registry electronic health records
(CALIBER 1998–2010, England) of patients with newly diagnosed atrial fibrillation, acute myocardial infarction,
unstable angina or stable angina with the aim to develop algorithms for bleeding events. Using the developed
bleeding phenotypes, Kaplan-Meier plots were used to estimate the incidence of bleeding events and we used Cox
regression models to assess the prognosis for all-cause mortality, atherothrombotic events and further bleeding.
Results: We present electronic health record phenotyping algorithms for bleeding based on bleeding diagnosis in
primary or hospital care, symptoms, transfusion, surgical procedures and haemoglobin values. In validation of the
phenotype, we estimated a positive predictive value of 0.88 (95% CI 0.64, 0.99) for hospitalised bleeding. Amongst
128,815 patients, 27,259 (21.2%) had at least 1 bleeding event, with 5-year risks of bleeding of 29.1%, 21.9%, 25.3%
and 23.4% following diagnoses of atrial fibrillation, acute myocardial infarction, unstable angina and stable angina,
respectively. Rates of hospitalised bleeding per 1000 patients more than doubled from 1.02 (95% CI 0.83, 1.22) in
January 1998 to 2.68 (95% CI 2.49, 2.88) in December 2009 coinciding with the increased rates of antiplatelet and
vitamin K antagonist prescribing. Patients with hospitalised bleeding and primary care bleeding, with or without
markers of severity, were at increased risk of all-cause mortality and atherothrombotic events compared to those
with no bleeding. For example, the hazard ratio for all-cause mortality was 1.98 (95% CI 1.86, 2.11) for primary care
bleeding with markers of severity and 1.99 (95% CI 1.92, 2.05) for hospitalised bleeding without markers of severity,
compared to patients with no bleeding.
Conclusions: Electronic health record bleeding phenotyping algorithms offer a scalable approach to monitoring
bleeding in the population. Incidence of bleeding has doubled in incidence since 1998, affects one in four
cardiovascular disease patients, and is associated with poor prognosis. Efforts are required to tackle this iatrogenic
epidemic.
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Background
Bleeding is amongst the most common serious side
effects of modern medicine, but clinicians and health
systems lack basic information on how to define and
monitor the occurrence and severity of bleeding in pop-
ulations. Multiple clinical guidelines make recommenda-
tions for the use of antithrombotic drugs across diseases
[1, 2]. Increases in the burden of common cardiovascular
diseases (CVDs), new drugs (e.g. P2Y12 receptor an-
tagonists and direct anticoagulants), implementation
of long-standing trial evidence (e.g. aspirin in the sec-
ondary prevention of CVD) and prolongation (lifelong)
of regimes which were initially introduced for fixed
durations (e.g. dual antiplatelet therapy after acute
myocardial infarction (MI)) have led to increasing
antithrombotic use [3–5].
Bleeding risk stratification [3], prevention [6, 7] and
management [8, 9] are mentioned in several guidelines.
However, specific recommendations at the individual
and population level, in specific subpopulations (e.g.
with concomitant proton pump inhibitor prescription
[10]), are lacking largely due to lack of data regarding
the population burden (incidence, time trends and progno-
sis) of bleeding in people with common CVDs, time trends
in incidence of bleeding of different severities with increas-
ing antithrombotic use. Bleeding risks, often defined differ-
ently, have been described in individual diseases (atrial
fibrillation (AF) [11], acute coronary syndromes [12] and
stable coronary disease [13]), but there are no studies com-
paring the risks across common CVDs.
A central reason for these uncertainties is the lack of
standardised definitions to measure bleeding occurrence
and severity which are scalable across populations and
different national health systems, where manual adjudi-
cation of case records (used in small numbers of bleed-
ing events, e.g. in trials, or consented research cohorts
[10, 14, 15]) is neither practical nor feasible. Consistent
definitions of disease and health conditions using diverse
electronic health records (EHR) across primary and hos-
pital care can be used to make valid comparisons across
countries [16–18]. Previous EHR studies of bleeding
endpoints have been restricted by setting [19–21],
anatomical site (e.g. upper gastrointestinal bleeding
[22–24]) or data (insurance or administrative claims
[25, 26]) (Additional file 1: Table S1). The efficient use
of information related to bleeding (e.g. diagnosis, ana-
tomical site, fatality, length of hospital stay, haemoglo-
bin, transfusion, endoscopy, surgical interventions)
could help to generate population estimates of bleed-
ing occurrence and severity.
We sought to address the following questions: First,
how can population-based EHR, spanning primary and
hospital care, be used to define valid, replicable algo-
rithms of bleeding occurrence and bleeding severity?
Second, what is the long-term cumulative incidence of
bleeding events across patients with incident AF, acute
MI and unstable and stable angina who are prescribed
with different antiplatelet and anticoagulation regimens?
Third, to what extent has the incidence of bleeding in-
creased over time with the changes in antithrombotic
management? Fourth, to what extent is bleeding of
differing severity associated with long-term prognosis in
terms of all-cause mortality, atherothrombotic events
and recurrent bleeding?
We used the CALIBER [27] research platform of linked
primary, hospital, myocardial ischaemia registry and mor-
tality data. EHR phenotypes have been developed in
CALIBER for acute MI [18], AF [28] and stable coronary
disease [29]. Cohort studies of their associations with
blood pressure [30], diabetes [31], smoking [32], socio-
economic deprivation [33], rheumatoid arthritis [34],
alcohol consumption [35] and neutrophil counts [36]
have supported their validity.
Methods
Linked electronic health records
We used data from the CALIBER [27] resource. CALI-
BER links EHR from primary care general practices
(Clinical Practice Research Datalink [CPRD]), hospital
admissions (Hospital Episode Statistics [HES]), myocar-
dial ischaemia registry (Myocardial Ischaemia National
Audit Project [MINAP]) and cause-specific mortality
(Office for National Statistics [ONS]) data in England.
The 4% sample of England’s population in CPRD avail-
able for linkage is representative in terms of age, sex and
overall mortality [37–39]. In CALIBER, EHR disease
phenotypes [40] have been developed through collabora-
tions between clinicians, epidemiologists and statisti-
cians, and a number of risk factors and cardiovascular
and non-cardiovascular disease endpoints have been
validated for cardiovascular research [18, 27–36].
The study was approved by the Independent Scien-
tific Advisory Committee of the Medicines and Health-
care products Regulatory Agency in the UK, protocol
number 14_133.
Study population
The study population consisted of patients with CVD, i.e.
those who were potential candidates for antiplatelet and/
or vitamin K antagonist (VKA) therapy, in CALIBER
during 1997–2010. The study period was chosen to reflect
stable prescribing practice, with only warfarin and anti-
platelet agents, before the introduction of multiple directly
acting anticoagulants. To define this population, we used
pre-existing validated disease phenotypes [https://www.
caliberresearch.org/portal]. Patients were eligible if they
were aged 18 years and above and entered the cohort at
their first diagnosis of AF, acute MI, unstable angina or
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stable angina in primary or hospital care records. They
were followed up until death, transfer out of their primary
care practice (i.e. loss to follow-up) or the date of adminis-
trative censoring (March 2010).
We analysed baseline characteristics of patients stratified
by initial CVD. Using prescribing data, we summarised
therapy duration (median and interquartile range days) of
between cohort entry and first bleeding event. To calculate
the duration, a patient’s prescription was assumed to be
continuous if issued within 90 days of the previous one (90
days is the longest allowed duration of prescriptions in the
UK). Treatments were grouped as aspirin monotherapy,
adenosine diphosphate (ADP) receptor inhibitor monother-
apy, dual antiplatelet therapy (aspirin and ADP receptor
inhibitor), VKA monotherapy, VKA and one antiplatelet
(aspirin or ADP receptor inhibitor) and triple therapy
(VKA, aspirin and ADP receptor inhibitor).
Electronic health record data relevant to definition of
bleeding phenotypes
Within CALIBER, bleeding events were captured in pri-
mary care data (Read terms), hospital admissions admin-
istrative data (ICD-10 terms) and death registry (ICD-9
and ICD-10 terms) (Additional file 1: Table S2). The
description of the terms used contained information on
the anatomical site of bleeding. Hospital records indi-
cated the diagnosis position (i.e. primary or secondary
reason for hospitalisation), and the length of hospitalisa-
tion was calculated using admission and discharge dates.
Procedures relevant to bleeding (transfusion, bleeding
surgical interventions and endoscopy) were captured in
hospitalisation records using OPCS codes. Drug pre-
scriptions were available in primary care data, classified
according to the British National Formulary (BNF) chap-
ter. Clinical biomarkers such as haemoglobin were also
captured in primary care.
Algorithmic combinations to define bleeding EHR
phenotypes
The construction of the CALIBER bleeding EHR pheno-
type (Fig. 1) is fully explained in Additional file 1:
Methods S3. In short, we applied a structured approach
to phenotyping, previously demonstrated by Morley
et al. [28], involving iterative steps of diagnosis code re-
views, descriptive analyses and expert input. We used pub-
lished trial protocols of the definition of major bleeding [14,
15, 41] to identify candidate markers of bleeding severity.
We included the sub-set of markers which were available in
the EHR (for example, the HES data does not record
haemoglobin measurements) and evaluated the associations
with short-term mortality in order to develop the severe
bleeding EHR phenotype. We defined fatal bleeding as a
bleeding cause of death (underlying or otherwise) in the na-
tional death registry or all-cause death within 7 days of a
bleeding record in primary or hospital care. We identified
four markers of bleeding severity available within our data:
(1) bleeding as a primary reason for hospitalisation com-
bined with at least 14 days hospitalisation, (2) bleeding site
(intracranial, ruptured aortic aneurysm or haemopericar-
dium, (3) bleeding from more than one site on the same
day and (4) a transfusion record in hospital care within 30
days of a bleeding record.
We classified non-fatal bleeding events as hospitalised or
primary care with further markers of severity (henceforth
referred to as ‘hospitalised+MS’ and ‘primary care+MS’)
and hospitalised or primary care without markers of sever-
ity (referred to as ‘hospitalised’ and ‘primary care’). For pa-
tients with no bleeding code in either primary care or
hospital records, possible bleeding events may be inferred
where there are records that provide evidence suggesting
bleeding, for example, transfusions and low haemoglobin.
Statistical analysis
Validation of the hospitalised bleeding phenotype
We validated the hospitalised bleeding part of the pheno-
type algorithm through manual case note review amongst
consented patients in the SIGNUM prospective stroke co-
hort at 2 large NHS Trusts (University College London
Hospitals NHS Foundation Trust and King’s College
Hospital NHS Foundation Trust). Two clinicians (blinded
to the ICD-10 and OPCS-4 codes recorded) reviewed the
entire hospital record (charts, referral letters, discharge
letters, imaging reports) for 283 stroke patient hospital ep-
isodes. The hospital record corpus (14,364,947 words in
total) was made available as single text files per patient,
through the use of CogStack [42], method of enterprise-
wide retrieval and extraction architecture for structured
and unstructured information which integrates data across
multiple EHR systems in a hospital. Bleeding assignments
from the clinicians’ review were compared with those
from the bleeding algorithm, and we estimated the posi-
tive predictive value (PPV), negative predictive value
(NPV), sensitivity and specificity using the case review
data as the gold standard.
Cumulative bleeding incidence in four cardiovascular diseases
The incidence of any bleeding and fatal, hospitalised+MS
or primary care+MS bleeding was assessed using Kaplan-
Meier plots stratified by CVD-type AF, acute MI, unstable
angina or stable angina.
The association between antithrombotic prescribing and
bleeding
Cox proportional hazard models were used to estimate the
hazard ratios for the association between antithrombotic
therapies and first bleeding event of any severity and fatal
or bleeding+MS event. Antithrombotic therapy prescrip-
tions were included in the models as a time-dependent
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variable. Possible states were no antithrombotic therapy
(the reference group), aspirin, ADP receptor inhibitor, dual
antiplatelet therapy, vitamin K antagonist, vitamin K an-
tagonist and one antiplatelet (aspirin or ADP receptor
inhibitor), and triple therapy. Patients were followed up
until their first bleeding event of any severity and until
their first fatal or bleeding+MS event. The Cox models
were adjusted for age and sex.
Time trends in bleeding
We estimated the number of fatal, hospitalised+MS, pri-
mary care+MS, hospitalised and primary care bleeding
events per 1000 patients at monthly intervals between
1997 and 2010. To do this, we divided the number of
bleeding events recorded by the total number of patients
at risk each month. Loess smoothed lines were fitted to
detect changes in incidence over time. Similarly, we esti-
mated the time trends for the number of antithrombotic
prescriptions issued each month.
Prognosis following bleeding
We used Cox proportional hazard models to estimate
the hazard ratios (HR) for the association between first
bleeding events, all-cause mortality and atherothrombo-
tic events (composite of cardiovascular death, ischaemic
or unspecified stroke, or MI). Bleeding severity (hospita-
lised+MS, primary care+MS, hospitalised, primary care
and inferred) was treated as a time-dependent variable
in the models to prevent immortal time bias. The pos-
sible bleeding variable states were no bleeding (reference
group), primary care, primary care+MS, hospitalised or
hospitalised+MS. All patients started follow-up in the no
bleeding state and changed to the relevant bleeding state
at the time of their first bleeding event. Models were
also adjusted for age, sex and baseline disease history
(diabetes, stroke, peripheral arterial disease, cancer, renal
disease, peptic ulcer, bleeding diatheses, chronic an-
aemia). We also explored the risk of recurrent bleeding
in the subgroup of patients that had non-fatal bleeding
events using Kaplan-Meier plots, following patients from
the time of their first non-fatal bleeding event.
Modelling assumptions
The proportional hazards assumptions of Cox models
were checked using residual and log(−log) plots. All
analyses were performed using R version 3.2.
Fig. 1 Bleeding EHR phenotype algorithm for fatal, hospitalised, primary care and inferred bleeding with and without additional markers of severity
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Patient involvement
No patients were involved in setting the research ques-
tion and study outcome or the design and implementa-
tion of the study. There are no current plans to
disseminate the results with patient groups.
Results
Study population
Our study population consisted of 128,815 patients in
224 general practices newly diagnosed with AF, acute
MI, unstable angina and/or stable angina between 1997
and 2010. They were followed up for a total of 559,
161 person-years, a median of 3.7 years (IQR 1.5, 6.9).
The mean age was 71.5 years at cohort entry (43.8%
aged ≥ 75 years), and 48.5% were women.
Patient characteristics stratified by CVD are shown in
Table 1. AF patients were older than the coronary dis-
ease patients, and the majority were women. In contrast,
the coronary disease patients were mostly men. The AF
patients also had a higher prevalence of history of stroke,
renal disease, cancer and chronic anaemia. The majority
of patients in all four disease groups were prescribed at
least one antithrombotic drug between cohort entry and
first bleeding event or end of follow-up in those who did
not bleed.
Applying the CALIBER bleeding EHR phenotype algorithm
The bleeding algorithm is shown in Fig. 1. We identified
39,804 bleeding records from 27,259 (21.2%) patients in our
cohort. 59.4% of coded bleeding events were captured in
primary care, 50.2% in hospital admissions and 3.8% events
in death registry. Allowing a 30-day window, only 13.2% of
coded bleeding events were captured in 2 or more data
sources. The overlap of bleeding events between the data
sources used is shown in Additional file 1: Figure S4.
We identified 1492 further possible bleeding events
occurring in 1144 patients with no bleeding diagnosis re-
corded in primary care or hospital records through the
following routes: transfusion and presence of iron defi-
ciency anaemia diagnosis within 30 days (n = 689) [1];
surgical procedures to arrest bleeding or for haematoma
evacuation (n = 477) [2]; haemoglobin < 10 g/dL, iron
deficiency anaemia diagnosis and endoscopic examin-
ation within 30 days and no cancer, liver or renal disease
records in the previous year (n = 249) [3]; transfu-
sion, haemoglobin < 10 g/dL and endoscopic examin-
ation within 30 days and no cancer, liver or renal
disease records in the year prior (n = 77) [4].
Validation of the hospitalised bleeding phenotype
In our validation sub-study of hospitalised bleeding in
the phenotype algorithm using ICD-10 and OPCS codes,
we estimated a PPV of 0.88 (95% CI 0.64, 0.99), a NPV
of 0.98 (0.95, 0.99), a sensitivity of 0.71 (0.48, 0.89) and a
specificity of 0.99 (0.97, 1.00) (Additional file 1: Table S5).
The ICD-10 codes that were recorded for the false-
negative cases (clinicians identified bleeding in the case
notes, but the algorithm did not find bleeding in the
codes) are presented in Additional file 1: Table S6. The
clinicians’ review of free text identified seven patients with
a CT scan report of haemorrhagic transformation of
stroke, which did not have a bleeding as the primary cause
of admission. (Additional file 1: Table S7).
Cumulative incidence of any bleeding and fatal bleeding
or bleeding with markers of severity
At 5 years, 29.1% (95% CI 28.2, 29.9%) of AF patients,
21.9% (21.2, 22.5%) of MI patients, 25.3% (24.2, 26.3%)
of unstable angina patients and 23.4% (23.0, 23.8%) of
stable angina had bleeding of any kind (Fig. 2). Risks of
fatal bleeding, hospitalised+MS or primary care+MS
bleeding events at 5 years were 9.9% (9.3, 10.4%) for AF
patients, 6.1% (5.8, 6.5%) for MI patients, 6.8% (6.0,
7.2%) for unstable angina patients and 5.7% (5.5, 5.9%)
for stable angina.
Time trends in bleeding incidence and antithrombotic
prescribing
The estimated number of hospitalised+MS bleeding events
per 1000 active patients increased from 0.32 (0.24, 0.40) in
January 1998 to 0.54 (0.45, 0.62) in December 2009. Con-
trarily, in primary care+MS, bleeding events per 1000 active
patients decreased from 0.80 (95% CI 0.70, 0.91) in January
1998 to 0.34 (0.23, 0.45) in December 2009. The incidence
of fatal bleeding remained steady (Fig. 3a).
There were increases in hospitalised and primary care
bleeding events without markers of severity (Fig. 3b). The
estimated number of hospitalised bleeding events per
1000 active patients increased from 1.02 (0.83, 1.22) in
January 1998 to 2.68 (2.49, 2.88) in December 2009, and
for primary care bleeding events, the increase was from
1.70 (1.44, 1.95) to 3.31 (3.06, 3.57). This corresponded to
the rise of rates of prescribed antithrombotic therapies
over the study period (Fig. 3c). From January 1998 to De-
cember 2009, the increase in the number of prescriptions
issued per 1000 active patients for aspirin, ADP receptor
inhibitor and VKA was 147.9 (95% CI 127.4, 168.3) to
465.1 (444.6, 485.6), 2.8 (0.2, 5.4) to 94.8 (92.2, 97.4) and
22.7 (19.2, 26.1) to 83.7 (80.2, 87.1), respectively.
Overall, patients prescribed with more aggressive anti-
thrombotic therapies (dual antiplatelet therapy, vitamin K
antagonists and triple therapy) had a significantly higher
risk of bleeding events compared with those not pre-
scribed antithrombotic therapies (Fig. 4). Compared with
those not prescribed antithrombotic therapies, patients
who were prescribed triple therapy had 3.4 (2.6, 4.4) times
increased risk of any bleeding and 5.7 (3.7, 8.7) times in-
creased risk of fatal or bleeding+MS events.
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Table 1 Baseline characteristics of people with four common cardiac diseases
Atrial fibrillation
(n = 27,061)
Myocardial infarction
(n = 25,031)
Unstable angina
(n = 9500)
Stable angina
(n = 67,223)
Demographics
Age (years), mean (SD) 76.6 (12.8) 69.9 (13.5) 69.1 (13.2) 70.4 (12.3)
Age ≥ 75 years, n (%) 16,946 (62.6) 9982 (39.9) 3488 (36.7) 26,059 (38.8)
Women, n (%) 14,266 (52.7) 9206 (36.8) 4169 (43.9) 31,365 (46.7)
Highest quintile of deprivation (most deprived), n (%) 5137 (19.0) 4758 (19.1) 1947 (20.5) 13,837 (20.6)
Behaviours
Current smoker, n (%) 2277 (10.5) 3691 (19.5) 1058 (14.0) 6229 (11.4)
History of alcohol abuse, n (%) 2627 (9.7) 2430 (9.7) 908 (9.6) 6459 (9.6)
Medical history prior to cohort entrya
Type 2 diabetes, n (%) 2695 (10.0) 2922 (11.7) 1222 (12.9) 8728 (13.0)
Ischaemic or unspecified stroke, n (%) 2169 (8.0) 1462 (5.8) 558 (5.9) 3435 (5.1)
Peripheral arterial disease, n (%) 2276 (8.4) 2147 (8.6) 865 (9.1) 6199 (9.2)
Renal disease, n (%) 2570 (9.5) 1731 (6.9) 694 (7.3) 4351 (6.5)
Non-metastatic cancer, n (%) 5427 (20.1) 3158 (12.6) 1155 (12.2) 8701 (12.9)
Metastatic cancer, n (%) 526 (1.9) 209 (0.8) 74 (0.8) 520 (0.8)
Peptic ulcer, n (%) 1814 (6.7) 1713 (6.8) 753 (7.9) 5074 (7.5)
Bleeding diatheses and coagulation disorders, n (%) 312 (1.2) 175 (0.7) 77 (0.8) 534 (0.8)
Chronic anaemia, n (%) 4982 (18.4) 2808 (11.2) 1198 (12.6) 8125 (12.1)
Biomarkers at cohort entryb
SBP (mmHg), mean (SD) 140 (21.8) 143 (21.2) 142 (21.2) 142 (20.5)
% Missing 29.7 33.2 25.8 21.6
Haemoglobin (g/dL), mean (SD) 12.9 (1.97) 13.5 (1.91) 13.5 (1.75) 13.6 (1.69)
% missing 56.2 65.9 62 59.1
Creatinine (mmol/L), mean (SD) 107 (59.1) 108 (56.1) 105 (55.9) 102 (46.1)
% missing 49.5 57.6 54.1 49.7
Antithrombotic therapies (n, %) and duration (median, IQR) during follow-upc
Any antithrombotic therapy 16,868 (62.3) 19,950 (79.7) 7947 (83.7) 55,619 (82.7)
Aspirin monotherapy 10,787 (39.9) 16,511 (66.0) 6695 (70.5) 48,262 (71.8)
Duration (days) 382 (114, 908) 791 (267, 1742) 765 (268, 1691) 842 (305, 1752)
ADP receptor inhibitor monotherapy 1264 (4.7) 3683 (14.7) 1425 (15.0) 7351 (10.9)
Duration (days) 150 (46, 486) 94 (30, 376) 121 (42, 495) 181 (52, 652)
Dual antiplatelet therapy 1594 (5.9) 8673 (34.6) 2417 (25.4) 9539 (14.2)
Duration (days) 186 (90, 426) 349 (143, 478) 272 (98, 488) 261 (90, 476)
VKA monotherapy 7149 (26.4) 1666 (6.7) 853 (9.0) 6287 (9.4)
Duration (days) 427 (146, 1083) 216 (82, 626) 318 (110, 844) 344 (113, 938)
VKA + 1 antiplatelet 3003 (11.1) 1426 (5.7) 637 (6.7) 3892 (5.8)
Duration (days) 85 (51, 163) 106 (55, 262) 90 (54, 228) 90 (51, 214)
VKA + 2 antiplatelets 266 (1.0) 321 (1.3) 102 (1.1) 430 (0.6)
Duration (days) 68.5 (39, 93.2) 68.0 (43, 116.0) 62.5 (39, 90.0) 57.0 (35, 84.0)
SD standard deviation, SBP systolic blood pressure, BMI body mass index, IQR interquartile range, ADP adenosine diphosphate, VKA vitamin K antagonist
aAny record prior to cohort entry
bNearest record to entry within 1 year prior to entry
cBetween cohort entry and 1st bleeding event or end of follow-up
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Fig. 2 Five-year risk of CALIBER bleeding from time of initial atrial fibrillation, acute myocardial infarction, unstable angina or stable angina (n = 128,815
patients). a Any bleeding (includes fatal, hospitalised+MS, hospitalised, primary care+MS and primary care bleeding events). b Fatal bleeding or
bleeding with further markers of severity (includes fatal, hospitalised+MS and primary care+MS bleeding events only). MS markers of severity
Fig. 3 Time trends of fatal, hospitalised and primary care bleeding events and antithrombotic prescribing 1998–2010 in CALIBER. a Fatal,
hospitalised+MS and primary care+MS bleeding events. b Hospitalised and primary care bleeding events. c Prescriptions for ADP receptor
inhibitors, aspirin and vitamin K antagonists. Fitted lines are Loess smoothed curves with shaded 95% confidence intervals. MS, markers of
severity; ATT, antithrombotic therapy; VKA, vitamin K antagonists
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Death and atherothrombotic events following first
bleeding event
Patients were at increased risk of all-cause mortality and
cardiovascular death, stroke or MI following their first
bleeding event, and this association was observed across
all bleeding severities (Fig. 5). Based on the magnitude of
relative risks for prognostic outcomes, three levels of
bleeding severity were identified: The greatest prognostic
risk was observed in hospitalised+MS bleeding (class I),
followed by hospitalised or primary care+MS or inferred
bleeding (class II). The lowest prognostic risk was asso-
ciated with primary care bleeding (class III).
Compared to patients with no bleeding, the adjusted
HR for all-cause mortality was 2.97 (2.84, 3.12) for
class I bleeding and 1.23 (1.19, 1.27) for class III
bleeding. Similarly, the adjusted HR for cardiovascular
death, stroke or MI events was 2.55 (2.38, 2.74) for
class I and 1.08 (1.04, 1.13) for class III bleeding.
Risk of recurrent bleeding increased following an
initial bleeding event (Additional file 1: Figure S8).
The cumulative risks were greater if the initial bleed-
ing event had further markers of severity. The 5-year
recurrent event rates of any bleeding and fatal, hospi-
talised+MS or primary care+MS bleeding were 32.4%
(31.8, 33.0), and 8.3% (7.9, 8.6), respectively. Amongst
patients who initially experienced a bleeding event
with markers of severity, their 5-year recurrent event
rate was 37.4% (36.0, 38.8) for any bleeding and
Fig. 4 The association between antithrombotic therapy prescribing and any bleeding and fatal or bleeding+MS events adjusted for age and sex.
HR, hazard ratio; MS, markers of severity
Fig. 5 The association between non-fatal bleeding severity classes and all-cause mortality and cardiovascular death, stroke or myocardial infarction
(vs no bleeding). Adjusted estimates are adjusted for age, sex and comorbidities. MS, markers of severity; HR, hazard ratio; CI, confidence interval;
CV, cardiovascular; MI, myocardial infarction
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23.1% (21.9, 24.3) for fatal, hospitalised+MS or pri-
mary care+MS bleeding.
Discussion
In a population-based study of linked primary care and
hospital EHR in 128,815 patients with newly diagnosed
common CVDs, we found that bleeding has doubled in in-
cidence since 1998, affects 1 in 4 patients and is associated
with poor prognosis in terms of all-cause mortality and
subsequent atherothrombotic events. The phenotype algo-
rithms made available here distinguish 3 prognostic clas-
ses of bleeding severity which may be used by health
systems and public health authorities to focus efforts to
tackle the growing population impact of bleeding on
health outcomes.
Bleeding EHR phenotype algorithm: importance of linked
electronic health records
We developed standardised and replicable EHR pheno-
typing algorithms for bleeding and severity measures
based on available clinical information across primary
and hospital care. The algorithms combine information
on diagnoses, procedures, transfusion and haemoglobin.
Unlike previous EHR studies which defined bleeding
events using bleeding codes only, we demonstrated the
depth of information readily available within linked EHR
and the capability to achieve a more granular case defin-
ition by combining diagnosis terms with continuous
measurements. Our results highlighted the importance
of using multiple linked data sources for defining and
validating the bleeding phenotype in EHR. No individual
data source used in this study had complete coverage of
coded bleeding diagnoses, transfusions, causes of death
and other bleeding relevant data, and only 13.2% of
bleeding cases were captured in multiple data sources
(Additional file 1: Figure S4). Individual components of
the phenotype, such as subgroups of the bleeding codes,
have been validated in previous studies in CPRD [24],
HES [23] and other EHR data sources [19–22, 25, 26],
and our analysis of outcomes following bleeding adequately
reflected expected results across levels of bleeding severity.
It has been previously shown that using hospital discharge
coding alone misses bleeding events compared with a
manual review of case notes [10]; nonetheless, our use of
multiple sources of EHR led to the estimation of a higher
incidence of bleeding at 1 year than in the study with
manual case note review.
Validation of bleeding phenotype
We provide new evidence of the validity of ICD-10
codes used in our bleeding EHR phenotype algorithm.
We found a PPV of 0.88, i.e. 88% of bleeding events
identified by these codes were indeed bleeding events ac-
cording to the independent review of the entire hospital
record by two clinicians, blinded to the ICD-10 code
assignment. The true incidence of bleeding is likely to be
even higher than that detected by existing EHR pheno-
types. We found that hospital codes have a sensitivity of
0.71 for detecting bleeds in the validation sub-study.
Previous reports of the sensitivity of EHR ICD code-
based algorithms differ in methodology and report sensi-
tivities ranging from 0.38 [10] to 0.80 [43]. In an analysis
of MI patients in a randomised trial setting, the sensitiv-
ity of a bleeding algorithm using ICD-9 codes has been
shown to be as high as 0.80 when considering all diagno-
sis and transfusion codes [43]. The higher sensitivity
may reflect the younger mean age (60 years vs > 70 years)
and the greater emphasis on complete coding for billing
optimisation in the USA, compared to the UK. This
highlights the potential importance of assessing the
context-specific validity of EHR phenotypes in different
EHR systems. Upon review of the false-negative cases in
our validation sub-study (Additional file 1: Table S6),
none had ICD-10 or OPCS-4 codes recorded for their
hospitalisation that we could reasonably include in the
bleeding phenotype algorithm in order to improve the
sensitivity. There have been few previous studies of the
validity of ICD-10 codes in the UK against full review of
hospital records, partly due to the difficulties in acces-
sing the hospital records; our informatics approach using
CogStack [42] for validation is scalable, replicable, rapid
and low cost. Due to privacy restrictions in accessing
primary care free-text data for research purposes, we
were unable to perform a validation sub-study to assess
the performance of the non-hospital bleeding in the
phenotype. However, previous studies have demon-
strated evidence of the accuracy and validity of primary
care records and bleeding definitions [24, 44].
Ascertaining the validity of EHR phenotypes is multi-
faceted and may be determined by comparing the event
rates and prognosis with previously published estimates
[45]. Further evidence of the ability of the EHR pheno-
type reported here to detect bleeds comes from compar-
ing the absolute risks that we report with studies based
on manual adjudication. We found a risk of bleeding of
7% at 1-year post-MI, compared to 5.0% (based on med-
ical claims) and 5.4% (based on physician adjudicated)
[43]. Our findings were consistent with prior studies of
bleeding trends over time [46], risk [43] and prognosis
[23, 47, 48]. Nonetheless, efforts are required by health
systems to improve the quality and completeness of data
to increase the sensitivity of EHR phenotypes.
Bleeding EHR phenotype: inferring bleeding events
A previous study showed that it is appropriate to infer
disease cases in EHR where diagnosis codes are absent
[28]. We identified 1144 patients with no coded bleeding
diagnosis present but exhibiting signs or symptoms of
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bleeding, such as low haemoglobin, iron deficiency an-
aemia or with a recorded bleeding-related procedure, ex-
cluding cases where bleeding may not be the cause of these
signs, symptoms and procedures (i.e. cancer, liver and renal
diseases). This highlights the potential of looking beyond
diagnosis codes in EHR to obtain more accurate estimates
of bleeding in safety studies of antithrombotic use. This
method requires validation, and cases identified using this
method should be considered possible bleeding events and
not definite.
Bleeding incidence in cardiovascular disease populations
At 5 years of follow-up, one in four patients with CVD
had any bleeding event and 6.5% had fatal or severe bleed-
ing. We provided a direct comparison of bleeding within
four CVDs with varying degrees of antithrombotic use
(Additional file 1: Table S9). AF had the highest bleeding
5-year rates both for any bleeding (29.1%) and fatal, hospi-
talised+MS or primary care+MS bleeding (9.9%). This is
likely to reflect the higher use and longer duration of pre-
scribed VKA and dual and triple therapy in AF patients.
However, the incidence of bleeding in MI, unstable angina
and stable angina patients was still relatively high.
Time trends in bleeding rates over the study period
So far, as we are aware, there have been no previous
studies evaluating the time trends in bleeding incidence
in common CVDs. In our study, we found that the rates
of hospitalised bleeding per 1000 patients more than
doubled from 1.02 in 1998 to 2.68 in 2009. We hypothe-
sised that the increased use of antithrombotic therapies
during this period would be associated with an increased
incidence of bleeding. We indeed did identify increases
in rates of hospitalised+MS, hospitalised and primary
care bleeding events over time, consistent with an in-
crease over the same time period. However, based on
the results of our study, we cannot distinguish the rela-
tive contributions to the observed increase in bleeding
incidence of the increasing range of available antithrom-
botic therapies, widening indications and changing
guidelines for their use over time. Because hospitals re-
ceive reimbursement based on the ICD codes at dis-
charge [49], it is possible that the observed increase in
the rate of bleeding is partly artefactual, i.e. due to better
recording over time. However, there are three lines of
evidence against such an artefact: (1) we also observed
increases in the rate of bleeding in an entirely separate
source of data from primary care, used for clinical deci-
sion making without any financial incentives to record
bleeding events; (2) this increase is consistent with previ-
ous evidence, of the increase in rates of intracerebral
haemorrhage in the UK between 1981 and 2006 [46];
and (3) prescribing of antithrombotic therapies, which is
known to increase the risk of bleeding complications,
has increased during the study period.
Prognosis following bleeding
These bleeding events were associated with poor out-
comes suggesting an increasing burden of bleeding on
healthcare systems and costs in England. Our analysis of
prognosis following a non-fatal bleeding event identified
three distinct levels of severity: I, hospitalised+MS; II,
hospitalised, primary care+MS or inferred bleeding; and
III, primary care (Fig. 5). This goes beyond the usual
dichotomised classification of bleeding as either major
or minor that is commonly reported. Increased bleeding
severity was strongly associated with increased risks of
all-cause mortality and atherothrombotic events. In par-
ticular, we found that bleeding diagnosed in primary
care, without acute hospitalisation, was associated with
adverse prognosis, both as class II and as class III (with
and without associated markers of severity, respectively).
Thus, all types of bleeding captured by the phenotype
are clinically relevant. The term ‘minor bleeding’ may be
misleading for clinicians, suggesting that no further ac-
tion is required; while our study suggests that even a
bleed in primary care without additional markers of se-
verity is associated with 23% increased risk of death. Our
findings are consistent with a previous study of bleeding
in AF trial participants which found impaired health
state utility even amongst ‘minor’ bleeds [48]. While we
have identified associations between bleeding and prog-
nosis, in our present analyses, we cannot claim these
associations to be causal.
Limitations of EHRs
EHRs have strengths and limitations for defining bleed-
ing. Strengths include the availability of relevant, con-
stantly updated information, at nationally representative
scale, with the opportunities for international compari-
son [17] and the low cost of acquiring the information.
The key limitations are the lack of structured informa-
tion (e.g. on bleeding severity) and inconsistency of data
models in different EHR systems, which makes it diffi-
cult to combine data from multiple sites. Widespread
adoption of clinically led, standardised data models such
as the openEHR framework (https://www.openehr.org/)
will help. A second limitation is that much of the infor-
mation in EHR systems is in free text, which is difficult
to access for research and to interpret. At a national
scale, information is lacking on acute haemoglobin
change, the number of units transfused and other details
of bleeding to support the classification of bleeding
severity. In clinical practice, these markers are used to
assess bleeding severity and have high prognostic value
[50]. Their addition to EHR phenotypes would be an im-
portant refinement to bleeding definitions. We showed
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some evidence that haemoglobin drop might contribute to
defining bleeding severity, but our data lacked haemoglo-
bin values measured within hospital admissions. The pre-
scribing data reported here was confined to primary care
and did not include drugs prescribed during hospitalisa-
tion or over-the-counter aspirin. Therefore, the rates of
prescribing reported may underestimate the true rates.
Clinical implications
Our study provides evidence of an iatrogenic epidemic,
demonstrating the public health burden of increasing
bleeding incidence and adverse prognosis, and suggests
three clinical implications.
First, by better identifying the bleeding risks and
events in EHR, the decision-making around antithrom-
botic therapy may be improved. It has been shown that
AF patients have been prescribed oral anticoagulants
despite being contraindicated due to bleeding risk, indi-
cating that patients and clinicians may outweigh the
benefits of stroke prevention over the possibility of
major bleeding [51]. Furthermore, bleeding has been
shown to be associated with discontinuation of warfarin
[52] thus highlighting the challenge of managing benefits
and harms of antithrombotic therapy. Clinicians should
ensure that the decision to prescribe antithrombotic
therapy is based on a personalised evaluation of both
bleeding risk and atherothrombotic risk in combination
with trial results [53]. Such an approach tailors drug
treatment decisions to an individual’s expected net bene-
fit and is able to incorporate a patient’s utility (or disutil-
ity) from bleeding and atherothrombotic events, for
example, in the setting of prolonged dual antiplatelet
therapy, have demonstrated the validity and feasibility
(with web calculators) of such an approach using readily
available clinical data [53]. Second, clinicians should be
aware that patients who experience bleeding events, even
those which are not hospitalised, are at particularly high
risk and may warrant more intense monitoring [48].
Third, we propose that bleeding events are continually
monitored and reported by organisations as part of the
quality of care and outcome reporting not just in single
cardiovascular diseases, but across whole health systems
and whole populations. In order to do this, health sys-
tems need open and, where possible, international stan-
dards for EHR bleeding phenotypes, which will require
further manual, expert refinement, in the light of system
changes and ongoing evaluations of accuracy. Indeed,
one general population survey of adults aged 45–75 years
conducted in the USA reported antiplatelet use in 47%
despite the small proportion of participants with estab-
lished cardiovascular disease [54]. We have shown that
the severe bleeding EHR phenotypes reported here
closely match the endpoints used in trials [29]. This sug-
gests that linked EHR can be used in ongoing reporting
to estimate the real-world impact of interventions, such
as the introduction of new drugs or changes in clinical
guidelines or health policy.
Future research
International standards for the EHR definition of bleed-
ing occurrence and severity using available national and
regional clinical records and based on the approach de-
scribed here should be developed. Transparent reporting
of EHR phenotype algorithms is required in order to
make bleeding research more replicable and to compare
the incidence and prognosis of bleeding of different se-
verities in different countries and across different health
systems [17]. This is important to understand the extent
to which, if any, newer antithrombotic agents such as
direct oral anticoagulants and ticagrelor are halting the
trend of increased incidence of bleeding or reducing the
severity of bleeding events. The method validation of
disease code-based EHR phenotypes against the full hos-
pital record reported here is scalable to other diseases
and other hospitals.
Conclusion
Bleeding is a major public health problem; it is common
in patients with CVD, the incidence of hospitalisation
for bleeding is increasing, and it is associated with high
mortality. The comprehensive and reproducible bleeding
EHR phenotype with three levels of severity that we have
developed is informative in mortality, risk of fatal or
non-fatal atherothrombotic events, and recurrent bleed-
ing. It can be used and further developed in EHR studies
of bleeding outcomes or antithrombotic safety.
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